Global Primary Hyperoxaluria Drug Market Research Report 2021

Global Primary Hyperoxaluria Drug Market Research Report 2021

  • QYResearch
  • January 2021
  • Pharmaceutical
  • 93 pages

Report Description

1
1
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
ALLN-230
DCR-PHXC
ALN-GO1
Others

Segment by Application
Hospital
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Allena Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Intellia Therapeutics Inc
OxThera AB

Have query on this report?

Make an Enquiry
1 Primary Hyperoxaluria Drug Market Overview
1.1 Product Overview and Scope of Primary Hyperoxaluria Drug
1.2 Primary Hyperoxaluria Drug Segment by Type
1.2.1 Global Primary Hyperoxaluria Drug Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 ALLN-230
List of Tables
Table 1. Global Primary Hyperoxaluria Drug Sales (K Pcs) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Primary Hyperoxaluria Drug Sales (K Pcs) Comparison by Application (2021-2027)
Table 3. Global Primary Hyperoxaluria Drug Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Primary Hyperoxaluria Drug Covered in This Study
Table 5. Global Primary Hyperoxaluria Drug Sales (K Pcs) of Key Manufacturers (2016-2021)

Success Stories

Our Clients